The "Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) - Market Insights, Epidemiology, and Market Forecast-2028" report provides an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PF-ILD in the United States, EU5 and Japan.
According to this research, the patient pool of PF-ILD includes the cases of IPF, iNSIP, unclassifiable IIPs, IPAF, RA-ILD, SSc-ILD, HP, sarcoidosis and other ILDs related to occupational exposures.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, Type-specific Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, Subtype-specific Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, and Total Prevalent Cases of PF-ILD in the 7MM) scenario of PF-ILD in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2028.
According to this research, the total prevalent population of Interstitial Lung Disease in seven major markets was 736,184 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2028). The total prevalent population of PF-ILD in seven major markets was 228,613 in 2017.
Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market Outlook
According to this research, the total market size of PF-ILDs in seven major markets was USD 233.19 million in 2017. The market size of PF-ILD is expected to increase at a significant CAGR during the study period (2017-2028).
Among all the seven major markets, the United States accounts for the highest market size of PF-ILD. In 2017, the market size of PF-ILD was found to be USD 158.73 million.
The current market size of PF-ILD is mainly attributed by corticosteroids, mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus, and cyclophosphamide. The market size is expected to increase during the forecast period (2019-2028), due to potential therapies nintedanib (Ofev) and pirfenidone (Esbriet).
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.